The next generation biopharmaceuticals
Board of Directors
Robert Burns, Ph.D. Chairman
Robert is a board member of Targovax ASA (OSE:TRVX). He has been CEO of three antibody discovery & development companies (Celldex – CLDX:NASDAQ; Affitech A/S – AFFI:OMX; and 4-Antibody AG – Basel) leading successful private investor exits for all three companies. He was also Chairman of Haemostatix Ltd until the successful divestment of the company to Ergomed plc – ERGO:LSE. Previously he has served in commercial and business development leadership positions at Ludwig Cancer Research (US), Oxford Glycosciences plc (UK), British Biotechnology plc (UK), Applied biotechnology Inc (US), and Corning Glassworks (US & UK).
Mathias Uhlén, Ph.D. Deputy Chairman
Prof. Uhlén is a co-founder of Affibody AB, and Professor of Biotechnology at the Royal Institute of Technology in Stockholm. He is a Program Director of the Swedish Human Protein (HPA) program, funded by the Knut and Alice Wallenberg foundation, and a Board member of Atlas Antibodies AB (Chairman), Antibodypedia AB (Chairman), Bure AB, Novozymes AS, Atlasab Intressenter AB and SweTree Technologies AB.
Jonathan Knowles, Prof., Ph.D. Director
Jonathan Knowles is currently professor in personalized health care at the Finnish Institute for Molecular Medicine at the University of Helsinki, and visiting chair at the University of Oxford. He also serves on the board of a number of biotech companies including Immunocore Ltd. (Chairman), Adaptimmune Ltd (Chairman) and Caris Life Sciences. In his most recent executive role he was president of group research at Roche and member of Roche’s Corporate Executive Committee. Dr Knowles was also a member of the Genentech Board for 12 years and a member of the Chugai Board for seven years.
Jakob Lindberg, Med. Lic. Director
Jakob Lindberg is CSO of Oncopeptides AB and board member of Atlas Antibodies AB och Alligator Bioscience AB. Mr. Lindberg holds a Med. Lic. in Molecular Immunology a MSc in pre-clinical medicine from the Karolinska Institutet in Sweden and a BA in Finance and Administration from the Stockholm University. He started his career as an analyst with Merrill Lynch in London and moved to consultancy with McKinsey in Stockholm, followed by a period in Gothenburg as CEO and co-founder of Cellectricon AB.
José F Suárez Director
José has been a Managing Director at Patricia Industries North America since 2015. José has more than 20 years of experience in venture capital and private equity and served as Managing Director for Investor Growth Capital, focusing on infrastructure technology, ranging from semiconductors to hardware systems and software. José received a B.A. in Asian Studies from Dartmouth College.
Gillian M. Cannon Director
Gillian M. Cannon is President of Alyvant LLC and board member of Alyvant LLC, President Emeritus of Castle Biotech LLC, and Advisory Board Member for HealthEgames. Dr. Cannon holds a Ph. D. in Health Administration in addition to an MBA and an undergraduate degree in Biochemistry. Gillian has held senior U.S., European and Global leadership positions at several pharmaceutical companies across a broad range of disciplines including Market Access, Outcomes Research, Sales Leadership, Marketing, Business Development and Strategic Planning. Prior to founding Alyvant and Castle Biotech, she was the President of North American Operations for UCB.
Camilla Sønderby Director
Camilla Sønderby is a board member of F2G Ltd and Healthcare Adviser at EQT Partners. She has more than 20 years of experience from senior positions in international pharmaceutical companies such as Takeda, Shire, Abbott, Roche, and Schering Plough. Camilla has been involved in the commercialization of pharmaceuticals, as well as R&D, patient safety and IR. She holds a degree in political science from the University of Copenhagen.
Anders Martin-Löf Director
Anders Martin-Löf is a board director of Cantargia AB. He has extensive experience as CFO in companies listed on the Stockholm stock exchange and has previously been CFO for Oncopeptides AB, Wilson Therapeutics AB and RaySearch Laboratories AB. He has also been head of investor relations and held various positions in business development at Swedish Orphan Biovitrum. Anders holds a BSc in Business Administration and Economics from Stockholm University and a MSc in Engineering Physics from KTH Royal School of Technology, Stockholm.
Affibodys latest Press releases
Affibody, ACELYRIN, and Inmagene Biopharmaceuticals Announce Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis Presented During 2022 European Alliance of Associations for Rheumatology Congress
Affibody in short
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
Upcoming reports Financial calendar
- Interim Report January to March 2020 (May 15, 2020)
- Interim Report January to June 2020 (August 21, 2020)
- Interim Report January to September 2020 (November 13, 2020)
- Year End Report 2020 (February 2021)